Statement of Principles concerning malignant neoplasm of the larynx No. 62 of 2013

Administered by Department of Veterans' Affairs

Legislation au F2013L01650 Not in force Legislative Instrument

Legislation content

REPATRIATION MEDICAL AUTHORITY

 

INSTRUMENT NO. 62 of 2013

 

VETERANS’ ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

EXPLANATORY NOTES FOR TABLING

 

 

  1. The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans’ Entitlements Act 1986 (the VEA), revokes Instrument No. 2 of 2006, determined under subsection 196B(3) of the VEA concerning malignant neoplasm of the larynx.

 

2.             The Authority is of the view that on the sound medical-scientific evidence available it is more probable than not that malignant neoplasm of the larynx and death from malignant neoplasm of the larynx can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(3) of the VEA a Statement of Principles, Instrument No. 62 of 2013 concerning malignant neoplasm of the larynx.  This Instrument will in effect replace the revoked Statement of Principles.

 

3.             The provisions of the Military Rehabilitation and Compensation Act 2004 (the MRCA) relating to claims for compensation commenced on 1 July 2004.  Claims under section 319 of the MRCA for acceptance of liability for a service injury sustained, a service disease contracted or service death on or after 1 July 2004 are determined by the Military Rehabilitation and Compensation Commission by reference to Statements of Principles issued by the Authority pursuant to the VEA.

 

4.             The Statement of Principles sets out the factors that must exist, and which of those factors must be related to the following kinds of service rendered by a person:

 

 eligible war service (other than operational service) under the VEA;

 defence service (other than hazardous service and British nuclear test defence service) under the VEA;

 peacetime service under the MRCA,

 

before it can be said that, on the balance of probabilities, malignant neoplasm of the larynx or death from malignant neoplasm of the larynx is connected with the circumstances of that service.

 

5.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 18 May 2011 concerning malignant neoplasm of the larynx in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

 

6.             The contents of this Instrument are in similar terms as the revoked Instrument.  Comparing this Instrument and the revoked Instrument, the differences include:

 

  • revising the definition of 'malignant neoplasm of the larynx' in clause 3;
  • revising factor 6(a) concerning 'smoking';
  • revising factor 6(b) concerning 'being in an atmosphere with a visible tobacco smoke haze';
  • new factor 6(d) concerning 'inhaling respirable asbestos fibres in an enclosed space';
  • new factor 6(e) concerning 'inhaling respirable asbestos fibres in an open environment';
  • revising factor 6(f) concerning 'alcohol';
  • new factor 6(g) concerning 'inhaling mist from a strong inorganic acid';
  • new factor 6(h) concerning 'stem cell or solid organ transplantation';
  • new factor 6(i) concerning 'human immunodeficiency virus';
  • new definition of 'mist from a strong inorganic acid' in clause 9;
  • revising the definitions of 'ICD-10-AM code', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'relevant service' in clause 9;
  • deleting the definition of 'an enclosed space'; and
  • specifying a date of effect for the Instrument in clause 11.

 

7.             Further changes to the format of the Instrument reflect the commencement of the MRCA and clarify that pursuant to subsection 196B(3A) of the VEA, the Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

 

8.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to malignant neoplasm of the larynx in the Government Notices Gazette of 18 May 2011, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority during the investigation.

 

9.             This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011. A Statement of Compatibility with Human Rights follows.

 

10.         The determining of this Instrument finalises the investigation in relation to malignant neoplasm of the larynx as advertised in the Government Notices Gazette of 18 May 2011.

 

11.         A list of references relating to the above condition is available to any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA.  Any such request must be made in writing to the Repatriation Medical Authority at the following address:

 

The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001

Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 62 of 2013

Kind of Injury, Disease or Death: Malignant neoplasm of the larynx

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have malignant neoplasm of the larynx;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must exist before it can be said that, on the balance of probabilities, malignant neoplasm of the larynx is connected with the circumstances of eligible service rendered by a person, as set out in clause 4 of the Explanatory Notes;
  • replaces Instrument No. 2 of 2006; and
  • reflects developments in the available sound medical-scientific evidence concerning malignant neoplasm of the larynx which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICSECR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICSECR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members; and
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Repatriation Medical Authority Instrument No. 62 of 2013, enacted under the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, addresses the need to update the Statement of Principles concerning malignant neoplasm of the larynx. This instrument was introduced to clarify the circumstances under which malignant neoplasm of the larynx can be considered related to particular kinds of service, thereby ensuring that eligible veterans and service members can receive appropriate medical treatment and compensation. The Authority, acting under the provisions of the Veterans’ Entitlements Act 1986, determined this Instrument based on the most recent sound medical-scientific evidence, replacing the previously revoked Instrument No. 2 of 2006. The policy objective is to facilitate claims for compensation by specifying the factors that must exist for malignant neoplasm of the larynx to be connected with service, thereby improving the medico-scientific quality of outcomes under the relevant Acts.

Scope and Application

The Repatriation Medical Authority Instrument No. 62 of 2013, established under the Veterans’ Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA), addresses the circumstances in which malignant neoplasm of the larynx can be considered related to service in the Australian Defence Force. This Instrument applies to veterans and current or former Defence Force members who have been diagnosed with malignant neoplasm of the larynx or have died from this condition, and who seek to make a claim under the VEA or the MRCA. It outlines the specific service-related factors that must exist for a claim to be considered valid, such as the type of service rendered and exposure to certain environmental or occupational hazards. The Instrument also replaces the previously revoked Instrument No. 2 of 2006 and reflects updated medical-scientific evidence. Notably, the Instrument does not apply to claims for conditions other than malignant neoplasm of the larynx and is limited to service-related factors specified within its clauses. This legislative instrument facilitates the assessment and review of claims by specifying the medical and service-related criteria that must be met for compensation to be granted.

Key Provisions

The Repatriation Medical Authority (RMA), under the Veterans’ Entitlements Act 1986 (VEA), has issued Instrument No. 62 of 2013 concerning malignant neoplasm of the larynx. This Instrument revokes the previous Instrument No. 2 of 2006 and establishes a new Statement of Principles. This new Statement of Principles outlines the circumstances under which malignant neoplasm of the larynx or death from such a neoplasm is likely to be connected with particular types of service, including eligible war service, defence service, and peacetime service. These provisions are particularly relevant to claims for compensation made under section 319 of the Military Rehabilitation and Compensation Act 2004 (MRCA), which came into effect on 1 July 2004. The Statement of Principles lists various factors that must be considered, such as exposure to certain environmental hazards or substances, including tobacco smoke, asbestos, and strong inorganic acids. It also revises some definitions and adds new factors, such as inhalation of respirable asbestos fibres in open environments and the impact of stem cell or solid organ transplantation. These provisions aim to provide a comprehensive framework for assessing claims related to malignant neoplasm of the larynx, ensuring that claimants and the Repatriation Commission have clear guidelines to follow. The obligations under this Act require the RMA to consider the sound medical-scientific evidence available when determining the connection between malignant neoplasm of the larynx and specific service circumstances. The RMA must also advertise its intention to undertake an investigation and invite submissions from relevant stakeholders. Once the investigation is complete, the RMA must issue a Statement of Principles that reflects the current evidence. This process ensures that the determinations are based on the most up-to-date and reliable scientific information. There are no specific offences or penalties outlined in this Instrument. However, failure to comply with the requirements set forth by the VEA and MRCA could potentially lead to disputes or legal challenges regarding compensation claims. The Authority is committed to ensuring that the Statement of Principles is compatible with human rights, promoting the rights of veterans, current and former Defence Force members, and their dependents. The Authority has assessed that this Legislative Instrument does not derogate from any human rights and, in fact, promotes several human rights by facilitating the assessment and determination of benefits and compensation.

Legal classification tags

Area of Law
Veterans' Law
Military Law
Instrument
Regulation
Concepts
Definitions & Interpretation
Regulatory Standards
Compliance Obligations
Enforcement Powers

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.